Document Detail


Adrenal Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: prediction of the efficacy of beta-blockade therapy and interest of unilateral adrenalectomy.
MedLine Citation:
PMID:  19564707     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Bilateral adrenalectomy is the standard treatment for Cushing's syndrome (CS) related to ACTH-independent bilateral macronodular hyperplasia (AIMAH), although it imposes life-long adrenal insufficiency. This study reports a clinical case in order to discuss the clinical interest of pharmacological beta-blockade of illegitimate membrane receptors and unilateral adrenalectomy as alternatives to bilateral adrenalectomy for treatment of CS due to AIMAH. Evidence for cortisol stimulation by upright posture and insulin-induced hypoglycemia in a patient with CS related to AIMAH led us to try beta-blockers as a therapeutic test and then as a first line treatment. Thus, a 3-day beta-blocker test (320 mg/d propranolol) induced normalization of cortisol secretion, with return of hypercortisolism at the end of the test. A long term treatment with 320 mg/d propranolol allowed sustained normalization of cortisol secretion and progressive disappearance of Cushingoid features but after 8 months the patient complained of Raynaud's syndrome and fatigue. Lowering propranolol dosage or switching to atenolol was less efficient to reduce cortisol levels. Unilateral adrenalectomy was then performed as a second line treatment, leading to normalisation of the 24h urinary cortisol without adrenal insufficiency. Long term control of blood pressure and glycemia were observed during a 7-year follow-up without beta-blocker. In conclusion, a 3-day propranolol test may identify patients with AIMAH who can benefit from a long term beta-blocker treatment. In case of intolerance to beta-blocking agents, unilateral adrenalectomy may allow for long term control of Cushing's syndrome related to AIMAH without adrenal insufficiency.
Authors:
T??nia L Mazzuco; Philippe Chaffanjon; Monique Martinie; Nathalie Sturm; Olivier Chabre
Related Documents :
9709947 - Adrenocortical overexpression of gastric inhibitory polypeptide receptor underlies food...
4470897 - The phenotype of human triploidy.
3003007 - Total extrinsic ophthalmoplegia as only paraneoplastic sign two years before x-ray diag...
10267 - Male pseudohermaphroditism, cryptorchism, and sertoli cell neoplasia in three miniature...
3071147 - Suppressed diluting segment reabsorption in bartter's syndrome: studies in 1 patient an...
18575887 - What's new in haemolytic uraemic syndrome?
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-06-30
Journal Detail:
Title:  Endocrine journal     Volume:  56     ISSN:  1348-4540     ISO Abbreviation:  Endocr. J.     Publication Date:  2009  
Date Detail:
Created Date:  2009-10-26     Completed Date:  2010-01-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9313485     Medline TA:  Endocr J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  867-77     Citation Subset:  IM    
Affiliation:
Service d'Endocrinologie, Centre Hospitalier Universitaire A. Michallon, Grenoble, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenal Glands / pathology*
Adrenalectomy / methods*
Adrenergic beta-Antagonists / therapeutic use*
Atenolol
Cushing Syndrome / drug therapy*,  surgery*
Female
Humans
Hydrocortisone / blood,  urine
Hyperplasia
Middle Aged
Posture
Propranolol / diagnostic use,  therapeutic use*
Treatment Outcome
Vasopressins / blood
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 11000-17-2/Vasopressins; 29122-68-7/Atenolol; 50-23-7/Hydrocortisone; 525-66-6/Propranolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Additional Beneficial Effects of Recombinant Growth Hormone in Alendronate-treated Patients with Idi...
Next Document:  Regulatory B cells.